159 / 1068
Polish Trial
Trans-Tasman
Limitations and Critical Points
•
Small (powered for 15% diff.)
•
Sphincter Preserv. dependent
•
Small
•
Local control: 10 % difference?
on surgical commitment
•
Poor compliance of CRT (69%)
•
Imbalance in adjuvant CTx
(46 vs 30% after CRT)
•
No central quality control
•
MRI staging not mandatory
•
Lack of info on MRF
•
Lack of info on TME, CRM
•
Imbalance in tumor location
(10% more low tumors in SCRT)